SCHEMBL5707604

SCHEMBL5707604

CCCC(=O)C1=CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 8/20 0.74
ESR2 Q92731 5/20 0.64
HSD17B1 P14061 5/20 0.57
MAPT P10636 4/20 0.57
STS P08842 4/20 0.57
LMNA P02545 3/20 0.57
CYP3A4 P08684 3/20 0.57
PGR P06401 2/20 0.57
AR P10275 2/20 0.57
SHBG P04278 2/20 0.57
AKR1B10 O60218 1/20 0.57
CYP1A2 P05177 1/20 0.57
SERPINA6 P08185 1/20 0.57
CYP19A1 P11511 1/20 0.57
AKR1B1 P15121 1/20 0.57
NFKB1 P19838 1/20 0.57
SLC6A4 P31645 1/20 0.57
OPRM1 P35372 1/20 0.57
SNCA P37840 1/20 0.57
HTR2B P41595 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7689539 0.88 ESR1 (0.57) ESR1ESR2HSD17B1STSCYP17A1
SCHEMBL5707489 0.87 ESR1 (0.73) ESR1ESR2HSD17B1MAPTSTS
SCHEMBL5159033 0.86 ESR1 (0.71) ESR1ESR2HSD17B1MAPTSTS
SCHEMBL7218327 0.86 ESR1 (0.71) ESR1ESR2HSD17B1MAPTSTS
SCHEMBL7218332 0.85 ESR1 (0.70) ESR1ESR2HSD17B1MAPTSTS
SCHEMBL7693147 0.85 USP2 (0.60) ESR1ESR2MAPTSTSLMNA
SCHEMBL5707483 0.84 ESR1 (0.69) ESR1ESR2HSD17B1MAPTSTS
SCHEMBL7949541 0.83 ESR1 (0.77) ESR1ESR2HSD17B1MAPTSTS
SCHEMBL7102035 0.83 ESR1 (0.67) ESR1ESR2HSD17B1MAPTSTS
SCHEMBL23759195 0.82 ESR1 (0.66) ESR1ESR2HSD17B1MAPTSTS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147124-B1 STEROID SULFATASE INHIBITORS AND METHODS FOR MAKING AND USING THE SAME UNIV HOLY GHOST DUQUESNE (US) 2006-08-30 EP disclosed
US-6436918-B1 SULFAMATE- AND AMINOCARBONYL- SUBSTITUTED STEROID RING SYSTEM HAVING 4 ATTACHED RINGS; THERAPEUTIC AND PROPHYLACTIC TREATMENTS FOR ESTROGEN DEPENDENT ILLNESSES. DUQUESNE UNIVERSITY OF THE HOLY GHOST 2002-08-20 US disclosed
US-20020068726-A1 Steroid sulfatase inhibitors and methods for making and using the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2002-06-06 US disclosed
US-6399595-B1 ANTITUMOR AGENTS; MAMMARY GLANDS DUQUESNE UNIVERSITY OF THE HOLY GHOST 2002-06-04 US disclosed
US-6376687-B1 THERAPY FOR ESTROGEN SENSITIVE DISEASES DUQUESNE UNIVERSITY OF THE HOLY GHOST 2002-04-23 US disclosed
US-6288050-B1 ADMINISTERING ESTRANESULFAMIC ACID DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT DUQUESNE UNIVERSITY OF THE HOLY GHOST 2001-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068726-A1 Steroid sulfatase inhibitors and methods for making and using the same STS, HSD17B11, CYP21A2 ESR1 58/4885ESR2 45/4885HSD17B1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.